Head-to-head evidence
Diazepam (Libervant) vs Diazepam (Valium)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABA-A receptor · full Epilepsy pipeline
Diazepam (Libervant)
Marketed by Aquestive Therapeutics, Inc.
NCT03428360 · Phase 3 · completed
The study treated 130 participants with diazepam buccal film in a single open-label group, without randomization, blinding, or a control arm. Its primary outcomes were safety event counts rather than a controlled clinical comparison, so the findings cannot establish comparative treatment effectiveness.
Diazepam (Valium)
Marketed by Roche
NCT03428360 · Phase 3 · completed
This was a single-group, open-label study with no randomization, blinding, or comparator arm; 149 participants were enrolled and 130 received study drug. Its primary safety outcomes were descriptive and had no formal between-group comparison, so the findings provide limited evidence for assessing diazepam buccal film.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Diazepam (Libervant)'s landscape · Diazepam (Valium)'s landscape